OA10985A - Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) - Google Patents

Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) Download PDF

Info

Publication number: OA10985A
Authority: OA; OAPI
Prior art keywords: compound; alkyl; mmol; add; equiv
Prior art date: 1996-09-04

Application number

OA9900046A

Other languages

English (en)

Inventor

Anthony Marfat

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-04

Filing date

1999-03-01

Publication date

2001-11-01

1999-03-01 Application filed by Pfizer filed Critical Pfizer

2001-11-01 Publication of OA10985A publication Critical patent/OA10985A/en

Links

108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 21
102000003390 tumor necrosis factor Human genes 0.000 title claims abstract description 21
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title claims abstract description 14
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title claims abstract description 14
238000004519 manufacturing process Methods 0.000 title claims abstract description 11
239000003112 inhibitor Substances 0.000 title description 3
125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 215
238000000034 method Methods 0.000 claims abstract description 68
241000124008 Mammalia Species 0.000 claims abstract description 10
230000005764 inhibitory process Effects 0.000 claims abstract description 8
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims description 51
229910052799 carbon Inorganic materials 0.000 claims description 51
125000000217 alkyl group Chemical group 0.000 claims description 49
-1 pyrimidinyi Chemical group 0.000 claims description 37
125000005843 halogen group Chemical group 0.000 claims description 31
125000001424 substituent group Chemical group 0.000 claims description 29
125000003118 aryl group Chemical group 0.000 claims description 24
125000003545 alkoxy group Chemical group 0.000 claims description 21
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims description 19
125000004093 cyano group Chemical group *C#N 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
125000003342 alkenyl group Chemical group 0.000 claims description 13
238000006243 chemical reaction Methods 0.000 claims description 12
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
229910052760 oxygen Inorganic materials 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 8
206010040070 Septic Shock Diseases 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
206010040047 Sepsis Diseases 0.000 claims description 6
150000001408 amides Chemical class 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
230000001684 chronic effect Effects 0.000 claims description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
201000004624 Dermatitis Diseases 0.000 claims description 4
201000004681 Psoriasis Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
206010006451 bronchitis Diseases 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
206010006895 Cachexia Diseases 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 3
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
201000004810 Vascular dementia Diseases 0.000 claims description 3
230000002917 arthritic effect Effects 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
230000001363 autoimmune Effects 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
125000001072 heteroaryl group Chemical group 0.000 claims description 3
208000018937 joint inflammation Diseases 0.000 claims description 3
201000004792 malaria Diseases 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
231100000241 scar Toxicity 0.000 claims description 3
208000011580 syndromic disease Diseases 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
230000009772 tissue formation Effects 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 2
206010037549 Purpura Diseases 0.000 claims description 2
241001672981 Purpura Species 0.000 claims description 2
208000025865 Ulcer Diseases 0.000 claims description 2
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
210000000988 bone and bone Anatomy 0.000 claims description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
125000002883 imidazolyl group Chemical group 0.000 claims description 2
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
201000008383 nephritis Diseases 0.000 claims description 2
125000002098 pyridazinyl group Chemical group 0.000 claims description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
206010037660 Pyrexia Diseases 0.000 claims 2
125000002947 alkylene group Chemical group 0.000 claims 2
206010025135 lupus erythematosus Diseases 0.000 claims 2
230000009885 systemic effect Effects 0.000 claims 2
206010001513 AIDS related complex Diseases 0.000 claims 1
201000005569 Gout Diseases 0.000 claims 1
206010018634 Gouty Arthritis Diseases 0.000 claims 1
102100039334 HAUS augmin-like complex subunit 1 Human genes 0.000 claims 1
101001035831 Homo sapiens HAUS augmin-like complex subunit 1 Proteins 0.000 claims 1
101000702560 Homo sapiens Probable global transcription activator SNF2L1 Proteins 0.000 claims 1
101000702544 Homo sapiens SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 Proteins 0.000 claims 1
102000044753 ISWI Human genes 0.000 claims 1
208000027418 Wounds and injury Diseases 0.000 claims 1
125000004450 alkenylene group Chemical group 0.000 claims 1
125000001589 carboacyl group Chemical group 0.000 claims 1
230000006378 damage Effects 0.000 claims 1
208000024908 graft versus host disease Diseases 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
206010039073 rheumatoid arthritis Diseases 0.000 claims 1
125000003107 substituted aryl group Chemical group 0.000 claims 1
125000001113 thiadiazolyl group Chemical group 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 6
238000002360 preparation method Methods 0.000 abstract description 3
239000000543 intermediate Substances 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 107
239000000203 mixture Substances 0.000 description 65
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 59
239000000243 solution Substances 0.000 description 57
239000011541 reaction mixture Substances 0.000 description 55
235000019439 ethyl acetate Nutrition 0.000 description 36
239000002585 base Substances 0.000 description 35
229940093499 ethyl acetate Drugs 0.000 description 35
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
239000012267 brine Substances 0.000 description 33
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 32
238000005481 NMR spectroscopy Methods 0.000 description 32
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
150000004702 methyl esters Chemical class 0.000 description 30
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
239000007858 starting material Substances 0.000 description 27
238000003756 stirring Methods 0.000 description 27
238000001035 drying Methods 0.000 description 26
239000007787 solid Substances 0.000 description 24
239000000499 gel Substances 0.000 description 23
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
238000001914 filtration Methods 0.000 description 19
150000002148 esters Chemical class 0.000 description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
238000010992 reflux Methods 0.000 description 16
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 15
239000000706 filtrate Substances 0.000 description 15
239000000843 powder Substances 0.000 description 14
239000000284 extract Substances 0.000 description 13
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
229910001868 water Inorganic materials 0.000 description 12
239000013078 crystal Substances 0.000 description 11
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
238000010189 synthetic method Methods 0.000 description 9
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 7
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
239000004533 oil dispersion Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000005160 1H NMR spectroscopy Methods 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
239000007832 Na2SO4 Substances 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
239000006260 foam Substances 0.000 description 5
125000004356 hydroxy functional group Chemical group O* 0.000 description 5
239000010410 layer Substances 0.000 description 5
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
125000004076 pyridyl group Chemical group 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910000029 sodium carbonate Inorganic materials 0.000 description 5
235000017550 sodium carbonate Nutrition 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
208000030507 AIDS Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
239000000010 aprotic solvent Substances 0.000 description 4
238000003556 assay Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
239000012043 crude product Substances 0.000 description 4
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
235000010288 sodium nitrite Nutrition 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
241000238366 Cephalopoda Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
229950006790 adenosine phosphate Drugs 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000012954 diazonium Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 3
230000005484 gravity Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000036303 septic shock Effects 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
230000007815 allergy Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000010936 aqueous wash Methods 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
238000006396 nitration reaction Methods 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
239000003880 polar aprotic solvent Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
235000011056 potassium acetate Nutrition 0.000 description 2
229960004109 potassium acetate Drugs 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000000171 quenching effect Effects 0.000 description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000001665 trituration Methods 0.000 description 2
238000010792 warming Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
VQXPUWAIJHXSON-MRVPVSSYSA-N (2r)-2-amino-n-phenylmethoxypropanamide Chemical compound C[C@@H](N)C(=O)NOCC1=CC=CC=C1 VQXPUWAIJHXSON-MRVPVSSYSA-N 0.000 description 1
AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
NUPWGLKBGVNSJX-UHFFFAOYSA-N 1-bromo-4-propylbenzene Chemical compound CCCC1=CC=C(Br)C=C1 NUPWGLKBGVNSJX-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
LNMBCRKRCIMQLW-UHFFFAOYSA-N 2-tert-butylsulfanyl-2-methylpropane Chemical compound CC(C)(C)SC(C)(C)C LNMBCRKRCIMQLW-UHFFFAOYSA-N 0.000 description 1
ISIQAMHROGZHOV-UHFFFAOYSA-N 3,5-dichloropyridin-4-amine Chemical compound NC1=C(Cl)C=NC=C1Cl ISIQAMHROGZHOV-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
KAWUBNUJMFOOOE-UHFFFAOYSA-N 3-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)CC(N)C1=CC(Br)=C(O)C(Br)=C1 KAWUBNUJMFOOOE-UHFFFAOYSA-N 0.000 description 1
MJFDEQYMXUJFQE-UHFFFAOYSA-N 3-amino-4-propylbenzoic acid Chemical compound CCCC1=CC=C(C(O)=O)C=C1N MJFDEQYMXUJFQE-UHFFFAOYSA-N 0.000 description 1
GXRWLPVXYJGNTK-UHFFFAOYSA-N 3-nitro-4-propylbenzoic acid Chemical compound CCCC1=CC=C(C(O)=O)C=C1[N+]([O-])=O GXRWLPVXYJGNTK-UHFFFAOYSA-N 0.000 description 1
NIGDWBHWHVHOAD-UHFFFAOYSA-N 4,6-dichloropyrimidin-5-amine Chemical compound NC1=C(Cl)N=CN=C1Cl NIGDWBHWHVHOAD-UHFFFAOYSA-N 0.000 description 1
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
VGJCCTYTFGHTHN-UHFFFAOYSA-N 4-bromo-2-nitro-1-propylbenzene Chemical compound CCCC1=CC=C(Br)C=C1[N+]([O-])=O VGJCCTYTFGHTHN-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
101100420681 Caenorhabditis elegans tir-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
229910017971 NH4BF4 Inorganic materials 0.000 description 1
101150020251 NR13 gene Proteins 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241001043916 Saitis Species 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
241000135164 Timea Species 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940064734 aminobenzoate Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
101150113676 chr1 gene Proteins 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000010828 elution Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
NIDZUMSLERGAON-UHFFFAOYSA-N ethyl 2-(methylamino)acetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNC NIDZUMSLERGAON-UHFFFAOYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
229960004979 fampridine Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002473 indoazoles Chemical class 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 description 1
108010083551 iturelix Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
CPQCSJYYDADLCZ-UHFFFAOYSA-N n-methylhydroxylamine Chemical compound CNO CPQCSJYYDADLCZ-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
CVNKFOIOZXAFBO-UHFFFAOYSA-J tin(4+);tetrahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[Sn+4] CVNKFOIOZXAFBO-UHFFFAOYSA-J 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Virology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA9900046A 1996-09-04 1999-03-01 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) OA10985A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2544696P	1996-09-04	1996-09-04

Publications (1)

Publication Number	Publication Date
OA10985A true OA10985A (en)	2001-11-01

Family

ID=21826124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900046A OA10985A (en)	1996-09-04	1999-03-01	Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Country Status (35)

Country	Link
US (1)	US6262040B1 (fr)
EP (1)	EP0931075A1 (fr)
JP (2)	JP3554337B2 (fr)
KR (1)	KR100338610B1 (fr)
CN (1)	CN1234031A (fr)
AP (1)	AP795A (fr)
AR (1)	AR008162A1 (fr)
AU (1)	AU724549B2 (fr)
BG (1)	BG64447B1 (fr)
BR (1)	BR9712005A (fr)
CA (1)	CA2264798A1 (fr)
CO (1)	CO4600636A1 (fr)
DZ (1)	DZ2303A1 (fr)
EA (1)	EA002113B1 (fr)
GT (1)	GT199700102A (fr)
HN (1)	HN1997000126A (fr)
HR (1)	HRP970478B1 (fr)
HU (1)	HUP9903248A3 (fr)
ID (1)	ID18157A (fr)
IL (1)	IL128642A0 (fr)
IS (1)	IS4979A (fr)
MA (1)	MA26439A1 (fr)
NO (1)	NO991048L (fr)
NZ (1)	NZ334213A (fr)
OA (1)	OA10985A (fr)
PA (1)	PA8437301A1 (fr)
PE (1)	PE107998A1 (fr)
PL (1)	PL332187A1 (fr)
SK (1)	SK27299A3 (fr)
TN (1)	TNSN97148A1 (fr)
TR (1)	TR199900481T2 (fr)
TW (1)	TW402595B (fr)
WO (1)	WO1998009961A1 (fr)
YU (1)	YU11299A (fr)
ZA (1)	ZA977903B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4373497B2 (ja)	1996-06-19	2009-11-25	ローン−プーラン・ロレ・リミテツド	置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
TR200001256T2 (tr) *	1997-11-04	2000-11-21	Pfizer Products Inc.	Terapötik olarak aktif bileşimler.
PL340753A1 (en) *	1997-11-04	2001-02-26	Pfizer Prod Inc	Substitution of indazolic bioisoster for cathechol in therapeutically active compounds
JP2000198734A (ja) *	1998-12-30	2000-07-18	Pfizer Inc	胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en)	1999-04-16	2001-02-20	Eastman Chemical Company	Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US7141581B2 (en)	1999-07-02	2006-11-28	Agouron Pharmaceuticals, Inc.	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2715683A1 (fr)	1999-08-21	2001-03-01	Nycomed Gmbh	Combinaison synergiste
WO2001047915A1 (fr) *	1999-12-23	2001-07-05	Icos Corporation	Inhibiteurs de phosphodiesterase specifique d'amp cyclique
US6362213B1 (en)	1999-12-23	2002-03-26	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
BR0110302A (pt)	2000-04-18	2003-01-14	Agouron Pharma	Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US7153871B2 (en) *	2001-01-22	2006-12-26	Memory Pharmaceuticals Corporation	Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en)	2001-01-22	2007-04-17	Memory Pharmaceuticals Corp.	Phosphodiesterase 4 inhibitors
WO2002094320A1 (fr) *	2001-05-23	2002-11-28	Tanabe Seiyaku Co., Ltd.	Compositions therapeutiques permettant de reparer la chondropathie
WO2002094321A1 (fr) *	2001-05-23	2002-11-28	Tanabe Seiyaku Co., Ltd.	Compositions favorisant la guérison d'une fracture osseuse
TWI221838B (en)	2001-08-09	2004-10-11	Tanabe Seiyaku Co	Pyrazinoisoquinoline compound or naphthalene compound
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
WO2003087333A2 (fr) *	2002-04-12	2003-10-23	Celgene Corporation	Modulation de differenciation de cellule souche et de cellule progenitrice, analyses et utilisations associees
WO2003102151A2 (fr) *	2002-05-30	2003-12-11	Celgene Corporation	Procedes d'utilisation d'inhibiteurs de jnk ou de mkk en vue de moduler la differenciation cellulaire et de traiter des troubles myeloproliferatifs et des syndromes myelodysplasiques
RU2354648C2 (ru) *	2002-07-19	2009-05-10	Мемори Фармасьютиклз Корпорейшн	Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
CA2492907A1 (fr)	2002-07-19	2004-01-29	Memory Pharmaceuticals Corporation	Inhibiteurs de phosphodiesterase 4 comprenant des analogues de diphenylamine et d'aniline n-substitues
EP1569908B1 (fr) *	2002-11-19	2010-09-15	Memory Pharmaceuticals Corporation	Pyridines N-Oxyde comme iNHIBITEURS DE LA PHOSPHODIESTERASE 4
US7109337B2 (en)	2002-12-20	2006-09-19	Pfizer Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
EA013248B1 (ru)	2002-12-20	2010-04-30	Пфайзер Продактс Инк.	Производные пиримидина для лечения патологического роста клеток
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
EA200501548A1 (ru)	2003-04-01	2006-02-24	Апплайд Резеч Системз Арс Холдинг Н.В.	Ингибиторы фосфодиэстераз при бесплодии
US7297709B2 (en) *	2003-05-22	2007-11-20	Abbott Laboratories	Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) *	2003-07-21	2009-02-19	Schumacher Richard A	Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja)	2003-09-03	2005-04-07	Yung Shin Pharmaceutical Industry Co Ltd	骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) *	2003-12-11	2010-03-31	Memory Pharm Corp	Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2007523938A (ja)	2004-02-27	2007-08-23	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾールの縮合誘導体
CN1922150A (zh)	2004-02-27	2007-02-28	霍夫曼-拉罗奇有限公司	吲唑衍生物以及含有它们的药物组合物
KR100844864B1 (ko)	2004-02-27	2008-07-09	에프. 호프만-라 로슈 아게	헤테로아릴-융합 피라졸로 유도체
MXPA06011658A (es)	2004-05-14	2006-12-14	Pfizer Prod Inc	Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
WO2005111016A1 (fr)	2004-05-14	2005-11-24	Pfizer Products Inc.	Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
WO2005111022A1 (fr)	2004-05-14	2005-11-24	Pfizer Products Inc.	Derives pyrimidiques pour le traitement de la croissance de cellules anormales
JP2008505969A (ja) *	2004-07-12	2008-02-28	メルク　エンド　カムパニー　インコーポレーテッド	ヒストン脱アセチル化酵素の阻害剤
US7601847B2 (en)	2004-10-26	2009-10-13	Wyeth	Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en)	2004-11-01	2006-07-01	Wyeth Corp	[(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
WO2006129158A2 (fr) *	2005-05-30	2006-12-07	Ranbaxy Laboratories Limited	Inhibiteurs de la phosphodiesterase de type iv
KR101011956B1 (ko)	2005-08-25	2011-01-31	에프. 호프만-라 로슈 아게	Ｐ３８ｍαｐ 키나아제 저해제 및 이의 사용 방법
EP1928866A1 (fr)	2005-09-05	2008-06-11	Ranbaxy Laboratories Limited	Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv
US7915286B2 (en)	2005-09-16	2011-03-29	Ranbaxy Laboratories Limited	Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2007210073B2 (en)	2006-01-31	2011-10-06	Array Biopharma Inc.	Kinase inhibitors and methods of use thereof
US20100056791A1 (en) *	2006-09-01	2010-03-04	Yasushi Kohno	Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
EP2091329A4 (fr) *	2006-12-05	2011-02-23	Univ Nat Chiao Tung	Composés d'indazole
PT2124944E (pt)	2007-03-14	2012-05-17	Ranbaxy Lab Ltd	Derivados de pirazolo[3,4-b]piridina como inibidores de fosfodiesterase
WO2010003084A2 (fr) *	2008-07-02	2010-01-07	Memory Pharmaceuticals Corporation	Inhibiteurs de la phosphodiestérase 4
ES2660892T3 (es) *	2009-03-23	2018-03-26	Merck Sharp & Dohme Corp.	Antagonistas del receptor P2X3 para el tratamiento del dolor
JP2013525370A (ja) *	2010-04-22	2013-06-20	ヤンセンファーマシューティカエヌ．ベー．	ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
EP3323820B1 (fr)	2011-02-28	2023-05-10	Epizyme, Inc.	Composés hétéroaryles bicycliques substitués condensés en 6,5
WO2015166370A1 (fr)	2014-04-28	2015-11-05	Pfizer Inc.	Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
KR20190078646A (ko) *	2016-11-18	2019-07-04	머크 샤프 앤드 돔 코포레이션	디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체
CN114450274A (zh)	2019-07-11	2022-05-06	伊斯凯普生物公司	作为lrrk2抑制剂的吲唑及氮杂吲唑
GB201910608D0 (en) *	2019-07-24	2019-09-04	Enterprise Therapeutics Ltd	Compounds
CN112694474B (zh) *	2019-10-23	2022-03-18	四川大学	吲唑类衍生物及其制备方法和用途
US20240279828A1 (en) *	2021-05-31	2024-08-22	Genscript Usa Inc.	Electrografted films for dna synthesis
TWI907890B (zh) *	2022-12-14	2025-12-11	國立成功大學	化合物及其合成方法與應用
CN116003325B (zh) *	2023-01-09	2025-04-25	南方医科大学	吲唑类化合物或其药学上可接受的盐及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE531433A (fr) *	1953-06-17
US4665397A (en)	1983-11-01	1987-05-12	Universal Photonics, Inc.	Apparatus and method for a universal electronic locking system
GB8524157D0 (en) *	1984-10-19	1985-11-06	Ici America Inc	Heterocyclic amides
JPH061350B2 (ja) *	1985-07-26	1994-01-05	コニカ株式会社	ハロゲン化銀写真感光材料
JPS6250751A (ja) *	1985-08-29	1987-03-05	Konishiroku Photo Ind Co Ltd	ハロゲン化銀写真感光材料
GB8609175D0 (en) *	1986-04-15	1986-05-21	Ici America Inc	Heterocyclic carboxamides
EP0381422B1 (fr) *	1989-02-02	1996-10-23	Yamanouchi Pharmaceutical Co. Ltd.	Dérivés de tétrahydrobenzimidazole
ES2102367T3 (es)	1990-05-18	1997-08-01	Hoechst Ag	Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
US5444038A (en) *	1992-03-09	1995-08-22	Zeneca Limited	Arylindazoles and their use as herbicides
AU695301B2 (en) *	1993-07-06	1998-08-13	Pfizer Inc.	Bicyclic tetrahydro pyrazolopyridines
GB9401460D0 (en) *	1994-01-26	1994-03-23	Rhone Poulenc Rorer Ltd	Compositions of matter
JPH09510191A (ja)	1994-02-17	1997-10-14	アメリカン・ホーム・プロダクツ・コーポレイション	ホスホジエステラーゼ阻害薬としての置換ビフェニル誘導体
WO1995027692A1 (fr)	1994-04-08	1995-10-19	Smithkline Beecham Corporation	Inhibiteurs du facteur de necrose tumorale a substitution biphenyle
JPH08143525A (ja) *	1994-11-21	1996-06-04	Banyu Pharmaceut Co Ltd	ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
EA002274B1 (ru) *	1996-06-25	2002-02-28	Пфайзер Инк.	Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
ATE211740T1 (de) *	1996-06-27	2002-01-15	Pfizer	Substituierte indazolderivate

1997
- 1997-08-25 PL PL97332187A patent/PL332187A1/xx unknown
- 1997-08-25 WO PCT/IB1997/001023 patent/WO1998009961A1/fr not_active Ceased
- 1997-08-25 BR BR9712005A patent/BR9712005A/pt not_active Application Discontinuation
- 1997-08-25 HU HU9903248A patent/HUP9903248A3/hu unknown
- 1997-08-25 JP JP51240998A patent/JP3554337B2/ja not_active Expired - Fee Related
- 1997-08-25 AU AU37813/97A patent/AU724549B2/en not_active Ceased
- 1997-08-25 EA EA199900183A patent/EA002113B1/ru not_active IP Right Cessation
- 1997-08-25 TR TR1999/00481T patent/TR199900481T2/xx unknown
- 1997-08-25 NZ NZ334213A patent/NZ334213A/xx unknown
- 1997-08-25 KR KR1019997001779A patent/KR100338610B1/ko not_active Expired - Fee Related
- 1997-08-25 US US09/254,346 patent/US6262040B1/en not_active Expired - Fee Related
- 1997-08-25 CA CA002264798A patent/CA2264798A1/fr not_active Abandoned
- 1997-08-25 YU YU11299A patent/YU11299A/sh unknown
- 1997-08-25 CN CN97199022A patent/CN1234031A/zh active Pending
- 1997-08-25 SK SK272-99A patent/SK27299A3/sk unknown
- 1997-08-25 EP EP97934678A patent/EP0931075A1/fr not_active Withdrawn
- 1997-08-25 IL IL12864297A patent/IL128642A0/xx unknown
- 1997-08-29 HN HN1997000126A patent/HN1997000126A/es unknown
- 1997-09-01 TW TW086112518A patent/TW402595B/zh not_active IP Right Cessation
- 1997-09-02 AR ARP970104001A patent/AR008162A1/es unknown
- 1997-09-02 PE PE1997000777A patent/PE107998A1/es not_active Application Discontinuation
- 1997-09-03 PA PA19978437301A patent/PA8437301A1/es unknown
- 1997-09-03 ZA ZA977903A patent/ZA977903B/xx unknown
- 1997-09-03 DZ DZ970153A patent/DZ2303A1/fr active
- 1997-09-03 GT GT199700102A patent/GT199700102A/es unknown
- 1997-09-03 TN TNTNSN97148A patent/TNSN97148A1/fr unknown
- 1997-09-03 MA MA24783A patent/MA26439A1/fr unknown
- 1997-09-03 ID IDP973065A patent/ID18157A/id unknown
- 1997-09-04 AP APAP/P/1997/001080A patent/AP795A/en active
- 1997-09-04 HR HR970478A patent/HRP970478B1/xx not_active IP Right Cessation
- 1997-09-04 CO CO97051473A patent/CO4600636A1/es unknown
1999
- 1999-02-16 IS IS4979A patent/IS4979A/is unknown
- 1999-02-22 BG BG103195A patent/BG64447B1/bg unknown
- 1999-03-01 OA OA9900046A patent/OA10985A/en unknown
- 1999-03-03 NO NO991048A patent/NO991048L/no unknown
2004
- 2004-03-23 JP JP2004083812A patent/JP2004217668A/ja active Pending

Also Published As

Publication number	Publication date
ZA977903B (en)	1999-03-03
EA002113B1 (ru)	2001-12-24
HN1997000126A (es)	1997-12-26
JP2000502724A (ja)	2000-03-07
HRP970478A2 (en)	1998-08-31
AU3781397A (en)	1998-03-26
PE107998A1 (es)	1999-01-30
TW402595B (en)	2000-08-21
KR20000068421A (ko)	2000-11-25
AR008162A1 (es)	1999-12-09
MA26439A1 (fr)	2004-12-20
HUP9903248A2 (hu)	2000-04-28
AU724549B2 (en)	2000-09-28
NO991048L (no)	1999-05-03
AP795A (en)	1999-12-28
PA8437301A1 (es)	1999-12-27
SK27299A3 (en)	2000-10-09
US6262040B1 (en)	2001-07-17
DZ2303A1 (fr)	2002-12-28
GT199700102A (es)	1999-02-25
YU11299A (sh)	2001-07-10
BR9712005A (pt)	1999-08-24
BG64447B1 (en)	2005-02-28
IS4979A (is)	1999-02-16
TR199900481T2 (xx)	1999-06-21
HUP9903248A3 (en)	2000-07-28
NO991048D0 (no)	1999-03-03
HRP970478B1 (en)	2002-10-31
EP0931075A1 (fr)	1999-07-28
IL128642A0 (en)	2000-01-31
WO1998009961A1 (fr)	1998-03-12
BG103195A (en)	1999-09-30
ID18157A (id)	1998-03-05
JP2004217668A (ja)	2004-08-05
EA199900183A1 (ru)	1999-08-26
NZ334213A (en)	2000-08-25
PL332187A1 (en)	1999-08-30
JP3554337B2 (ja)	2004-08-18
AP9701080A0 (en)	1997-10-31
TNSN97148A1 (fr)	2005-03-15
CO4600636A1 (es)	1998-05-08
CN1234031A (zh)	1999-11-03
CA2264798A1 (fr)	1998-03-12
KR100338610B1 (ko)	2002-05-27

Publication	Publication Date	Title
AP795A (en)	1999-12-28	Indazole derivatives.
KR100360633B1 (ko)	2002-11-13	Ｎｏｓ 억제제로서 유용한 6-페닐피리딜-2-아민 유도체
AU700337B2 (en)	1998-12-24	Aromatic compounds and pharmaceutical compositions containing them
FI120537B (fi)	2009-11-30	Trisubstituoituja fenyylijohdannaisia
KR101328273B1 (ko)	2013-11-14	세포 증식 질환의 치료를 위한 조성물 및 방법
KR102312088B1 (ko)	2021-10-14	항인플루엔자 바이러스 피리미딘 유도체
US5236937A (en)	1993-08-17	Pyridinyl compounds which are useful as angiotensin ii antagonists
JP4571863B2 (ja)	2010-10-27	抗痛覚過敏剤として有用なキナゾリノン誘導体
JP2008502628A (ja)	2008-01-31	ピリダジン−３（２ｈ）−オン誘導体およびｐｄｅ４の阻害剤としてのそれらの使用
JPH11209350A (ja)	1999-08-03	含窒素複素環誘導体およびその医薬
OA13247A (en)	2007-01-31	Phenyl or pyridyl amide coumpounds as prostaglandin E2 antagonists.
JP2003514808A (ja)	2003-04-22	抗炎症剤としての尿素誘導体
JP2005517723A (ja)	2005-06-16	炎症性疾患の治療用ケモカイン受容体阻害剤としてのピペリジン−４−イル尿素誘導体及び関連化合物
JP2019529386A5 (fr)	2020-11-19
JPH05230059A (ja)	1993-09-07	ベンゾジオキサン誘導体
WO1992006088A1 (fr)	1992-04-16	Derives d'indole utilises utilises comme agents antiallergiques et anti-inflammatoires
IL118663A (en)	2001-04-30	Compounds containing methylene-amino and oxy-linking groups, which are useful in analgesics, the process for their preparation, pharmaceutical mixtures containing them and their uses
US4782055A (en)	1988-11-01	Imidazopyridine compounds useful in the treatment of ulcers
JPH0460596B2 (fr)	1992-09-28
JP3626191B2 (ja)	2005-03-02	心臓血管系に活性な２−アミノ−１，２，３，４−テトラヒドロナフタレン誘導体
CN107108575A (zh)	2017-08-29	作为抗组胺剂的新型苯并咪唑衍生物
CN114436945B (zh)	2023-12-22	一种苯磺酰胺类化合物、制备方法及应用
JPH03294277A (ja)	1991-12-25	ピペリジン誘導体
JP2007526290A (ja)	2007-09-13	新規のリポキシゲナーゼインヒビターの使用
EP0773931A1 (fr)	1997-05-21	Derives de quinoleine antagonistes des leucotrienes